The prefrontal cortex: A target for antipsychotic drugs

Acta Psychiatrica Scandinavica

Volumn 121, Issue 1, 2010, Pages 11-21

  Artigas, F ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Antipsychotic drugs; Monoamines; Prefrontal cortex; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; HALOPERIDOL; NEUROLEPTIC AGENT; PHENCYCLIDINE; SEROTONIN 2 RECEPTOR; SEROTONIN RECEPTOR;

BASAL GANGLION; BRAIN CELL; BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM FUNCTION; COGNITION; DRUG MECHANISM; DRUG TARGETING; HISTOLOGY; HUMAN; MENTAL DISEASE; MONOAMINERGIC SYSTEM; NERVE CELL; PREFRONTAL CORTEX; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; VENTRAL TEGMENTUM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; CORPUS STRIATUM; HAPLORHINI; HUMANS; NEURAL PATHWAYS; NEURONS; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 72249084944     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2009.01455.x     Document Type: Review

References (92)

1. Fuster JM. The prefrontal cortex. anatomy, pysiology and neruropsychology of the frontal lobe. Philadelphia-New York, Lipincott-Raven, 1997.
2. Fuster JM. The prefrontal cortex - An undate: Time is of the essence. Neuron 2001 30 : 319 333.
3. Miller EK. The prefrontal cortex and cognitive control. Nat Rev Neurosci 2000 1 : 59 65.
4. Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. Annu Rev of Neurosci 2001 24 : 167 202.
5. Groenewegen HJ, Uylings HB. The prefrontal cortex and the integration of sensory limbic and autonomic information. Prog Brain Res 2001 126 : 3 28.
6. Fuster JM. Unit activity in prefrontal cortex during delayedresponse performance: neuronal correlates of transient memory. J Neurophysiol 1973 36 : 61 78.
7. Beaulieu C. Numerical data on neocortical neurons in adult rat, with special reference to the GABA population. Brain Res 1993 609 : 284 292.
8. De Felipe J. Cortical interneurons: from Cajal to 2001. Prog Brain Res 2002 136 : 215 238.
9. Kawaguchi Y, Kondo S. Parvalbumin, somatostatin and cholecystokinin as chemical markers for specific GABAergic interneuron types in the rat frontal cortex. J Neurocytol 2002 31 : 277 287.
10. Defelipe J, Hendry SHC, Jones EG. Visualization of chandelier cell axons by parvalbumin immunoreactivity in monkey cerebral cortex. Procc Natl Acad Sci USA 1989 86 : 2093 2097.
11. Steinbusch HWM. Distribution of serotonin-immunoreactivity in the central nervous system of the rat. Cell bodies and terminals. Neuroscience 1981 6 : 557 618.
12. Van Eden CG, Hoorneman EM, Buijs RM, Matthijssen MA, Geffard M, Uylings HB. Immunocytochemical localization of dopamine in the prefrontal cortex of the rat at the light and electron microscopical level. Neuroscience 1987 22 : 849 862.
13. Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: Adaptive gain and optimal performance. Annu Rev Neurosci 2005 28 : 403 450. (Pubitemid 41098911)
14. Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004 74 : 1 58.
15. Celada P, Artigas F. Serotonergic modulation of cortical activity. In : Tseng KY, Atzori M, eds. Monoaminergic modulation of cortical excitability. New York : Springer, 2007 : 67 89.
16. Atzori M, Salgado H, Tseng KY. Regulation of cortical functions by the central noradrenergic system: Emerging properties of an old friend. In : Tseng KY, Atzori M, eds. Monoaminergic modulation of cortical excitability. New York : Springer, 2007 : 197 207.
17. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990 13 : 266 271.
18. Alexander GE, Crutcher MD, Delong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990 85 : 119 146.
19. Masterman DL, Cummings JL. Frontal-subcortical circuits: the anatomic basis of executive, social and motivated behaviours. J Psychopharmacol 1997 11 : 107 114.
20. Ongür D, Price JL. The organization of networks within the orbital and medial prefrontal cortex of rats, monkeys and humans. Cereb Cortex 2000 10 : 206 219.
21. Carr DB, Sesack SR. Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons. J Neurosci 2000 20 : 3864 3873.
22. Hajós M, Richards CD, Szekely AD, Sharp T. An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience 1998 87 : 95 108.
23. 1A GABA(A) and glutamate receptors. J Neurosci 2001 21 : 9917 9929.
24. Puig MV, Artigas F, Celada P. Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex 2005 15 : 1 14.
25. Jodo E, Chiang C, Aston-Jones G. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience 1998 83 : 63 79.
26. Harrison PJ. The neuropathology of schizophrenia - A critical review of the data and their interpretation. Brain 1999 122 : 593 624.
27. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: A circuit based model of schizophrenia. Biol Psychiatry 1999 45 : 17 25.
28. Lewis DA, Lieberman JA. Catching up on schizophrenia: natural history and neurobiology. Neuron 2000 28 : 325 334.
29. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005 6 : 312 324.
30. Weinberger DR, Egan MF, Bertolino A et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001 50 : 825 844.
31. Elvevag B, Goldberg TE. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000 14 : 1 21.
32. Andreasen NC, Oleary DS, Flaum M et al. Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 1997 349 : 1730 1734.
33. Potkin SG, Alva G, Fleming K et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Am J Psychiatry 2002 159 : 227 237.
34. Catafau AM, Parellada E, Lomena FJ et al. Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease. J Nucl Med 1994 35 : 935 941.
35. Dierks T, Linden DE, Jandl M et al. Activation of Heschl's gyrus during auditory hallucinations. Neuron 1999 22 : 615 621.
36. Shergill SS, Brammer MJ, Williams SC, Murray RM, Mcguire PK. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry 2000 57 : 1033 1038.
37. Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 1995 376 : 572 575.
38. Dalley JW, Cardinal RN, Robbins TW. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 2004 28 : 771 784.
39. Clarke HF, Dalley JW, Crofts HS, Robbins TW, Roberts AC. Cognitive inflexibility after prefrontal serotonin depletion. Science 2004 304 : 878 880.
40. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 2007 10 : 376 384.
41. Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther 2007 113 : 523 536.
42. Goldman-Rakic PS, Muly EC III., Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Rev 2000 31 : 295 301.
43. Castner SA, Williams GV, Goldman-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 2000 287 : 20020 20022.
44. O'donnell P. Dopamine gating of forebrain neural ensembles. Eur J Neurosci 2003 17 : 429 435.
45. Day HE, Campeau S, Watson SJ. JR., Akil H. Distribution of alpha 1a-, alpha 1b- and alpha 1d-adrenergic receptor mRNA in the rat brain and spinal cord. J Chem Neuroanat 1997 13 : 115 139.
46. Pieribone VA, Nicholas AP, Dagerlind A, Hokfelt T. Distribution of alpha-1 adrenoceptors in rat brain revealed by in situ hybridization experiments utilizing subtype-specific probes. J Neurosci 1994 14 : 4252 4268.
47. Pazos A, Cortés R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain II Serotonin-2 receptors. Brain Res 1985 346 : 231 249. (Pubitemid 16241112)
48. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain I Serotonin-1 receptors. Brain Res 1985 346 : 205 230. (Pubitemid 16241111)
49. 1A receptor in the rat brain: correlation with receptor binding. J Neurosci 1992 12 : 440 453.
50. 2C receptors. Mol Brain Res 1994 23 : 163 178.
51. Kia HK, Miquel MC, Brisorgueil MJ et al. Immunocytochemical localization of serotonin(1A) receptors in the rat central nervous system. J Comp Neurol 1996 365 : 289 305.
52. Jakab RL, Goldman-Rakic PS. 5-Hydroxytryptamine(2A) serotonin receptors in the primate cerebral cortex: Possible site of action of hallucinogenic. antipsychotic drugs in pyramidal cell apical dendrites. Proc Natl Acad Sci USA 1998 95 : 735 740.
53. 2A receptor in the central nervous system of adult rat. J Comp Neurol 1999 409 : 187 209.
54. 2A receptors through a glutamate-dependent mechanism. J Neurosci 2001 21 : 9856 9866. (Pubitemid 34184070)
55. De Felipe J, Arellano JI, Gomez A, Azmitia EC, Munoz A. Pyramidal cell axons show a local specialization for GABA and 5-HT inputs in monkey and human cerebral cortex. Comp Neurol 2001 433 : 148 155.
56. 2A receptors in pyramidal and GABAergic neurons of the prefrontal cortex. Cereb Cortex 2004 14 : 1100 1109. (Pubitemid 39258165)
57. 2A receptors in pyramidal neurons of prefrontal cortex. Cereb Cortex 2004 14 : 281 299. (Pubitemid 38252721)
58. Puig MV, Santana N, Celada P, Mengod G, Artigas F. In vivo excitation of GABA interneruons in the medial prefrontal cortex through 5-HT3 receptors. Cereb Cortex 2004 14 : 1365 1375.
59. 2A receptors in working memory. J Neurosci 2002 22 : 2843 2854.
60. Nichols DE. Hallucinogens. Pharmacol Ther 2004 101 : 131 181.
61. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999 21 : S106 S115.
62. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence Neuropsychopharmacology 1998 18 : 63 101.
63. Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996 14 : 87 96.
64. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992 49 : 538 544.
65. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995 152 : 1444 1449.
66. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001 58 : 360 369.
67. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for "atypicality"?. Clin Neurosci Res 2003 3 : 108 117.
68. 1A receptor activation. Eur J Pharmacol 1997 338 : R3 R5.
69. 35S]GTPgammaS binding study. Eur J Pharmacol 1998 355 : 245 256.
70. 2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001 76 : 1521 1531.
71. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005 25 : 10831 10843.
72. 1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J. Neural Transm 2000 107 : 1229 1238.
73. Svensson TH. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs. Brain Res Rev. 2000 31 : 320 329.
74. 2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 2009 19 : 849 860.
75. 2A receptors. Cereb Cortex 2009 19 : 1678 1686.
76. 1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release. Reversal by antipsychotics drugs. J Neurochem 2003 87 : 831 842.
77. 2A) receptors: effect of antipsychotic drugs. Eur J Neurosci 2003 18 : 1235 1246. (Pubitemid 37120471)
78. 2A receptors. Relationship to thalamocortical afferents. Cereb Cortex 2003 13 : 870 882.
79. Suzuki Y, Jodo E, Takeuchi S, Niwa S, Kayama Y. Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats. Neuroscience 2002 114 : 769 779.
80. Jackson ME, Homayoun H, Bita Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 2004 101 : 8467 8472.
81. Kargieman L, Santana N, Mengod G, Celada P, Artigas F. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci USA 2007 104 : 14843 14848.
82. 2A sites for PCP-induced locomotion in the rat. Eur J Neurosci 1999 11 : 4419 4432.
83. Adams BW, Moghaddam B. Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biol Psychiatry 2001 50 : 750 757.
84. Amargós-Bosch M, López-Gil X, Artigas F, Adell A. Clozapine and olanzapine, but not haloperidol, suppresses serotonin efflux in medial prefrontal cortex elicited by phencyclidine and ketamine. Int J Neuropsychopharmacol 2006 9 : 565 573.
85. Amargós-Bosch M, Adell A, Artigas F. Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex. J Neurochem 2007 102 : 550 561.
86. López-Gil X, Babot Z, Amargós-Bosch M, Suñol C, Artigas F, Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007 32 : 2087 2097.
87. Celada P, Puig MV, Díaz-Mataix L, Artigas F. The hallucinogen DOI reduces low frequency oscillations in rat prefrontal cortex. Reversal by antipsychotic drugs. Biol Psychiatry 2008 64 : 392 400.
88. Väisänen J, Ihalainen J, Tanila H, Castrén E. Effects of NMDA-receptor antagonist treatment on c-fos expression in rat brain areas implicated in schizophrenia. Cell Mol Neurobiol 2004 24 : 769 780.
89. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007 27 : 11496 11500.
90. Lieberman JA, Stroup TS, Mcevoy JP et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 : 1209 1223.
91. Mcevoy JP, Lieberman JA, Stroup TS et al. Catie Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006 163 : 600 610.
92. Leucht S, Conves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia. Lancet 2009 373 : 31 41.